CoChat

Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial

Open access

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial analysis from JAVELIN Merkel 200, a phase 2, prospective, open-label, single-arm trial in mMCC, avelumab-a human anti-programmed death-ligand 1 (PD-L1) monoclonal antibody-showed promising efficacy and a safety profile that was generally manageable and tolerable. Here, we report the efficacy of avelumab after ≥1 year of follow-up in patients with distant mMCC that had progressed following prior chemotherapy for metastatic disease. PATIENTS AND METHODS: Patients received avelumab 10 mg/kg by 1-h intravenous infusion every 2 weeks until confirmed disease progression, unacceptable toxicity, or withdrawal. The primary endpoint was best overall response. Secondary endpoints included duration of response (DOR), progression-free survival (PFS), and overall survival (OS). RESULTS: Patients (N = 88) were followed for a minimum of 12 months. The confirmed objective response rate was 33.0% (95% CI, 23.3%-43.8%; complete response: 11.4%). An estimated 74% of responses lasted ≥1 year, and 72.4% of responses were ongoing at data cutoff. Responses were durable, with the median DOR not yet reached (95% CI, 18.0 months-not estimable), and PFS was prolonged; 1-year PFS and OS rates were 30% (95% CI, 21%-41%) and 52% (95% CI, 41%-62%), respectively. Median OS was 12.9 months (95% CI, 7.5-not estimable). Subgroup analyses suggested a higher probability of response in patients receiving fewer prior lines of systemic therapy, with a lower baseline disease burden, and with PD-L1-positive tumors; however, durable responses occurred irrespective of baseline factors, including tumor Merkel cell polyomavirus status. CONCLUSIONS: With longer follow-up, avelumab continues to show durable responses and promising survival outcomes in patients with distant mMCC whose disease had progressed after chemotherapy. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT02155647.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40425-017-0310-x

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Clinical activity of avelumab in patients with mMCC at ≥1 year of follow-up. Time to and duration of response and duration of treatment in 29 patients with a confirmed response. CR, complete response; DOR, duration of response; PD, progressive disease; PR, partial response
Fig. 1 Clinical activity of avelumab in patients with mMCC at ≥1 year of follow-up. Time to and duration of response and duration of treatment in 29 patients with a confirmed response. CR, complete response; DOR, duration of response; PD, progressive disease; PR, partial responseCC BY · PubMed Central
Fig. 2 Survival outcomes in patients with mMCC receiving avelumab. Kaplan-Meier estimates of (a) progression-free survival (PFS) and (b) overall survival (OS). Vertical lines indicate censored events. Also depicted in (a) are Kaplan-Meier estimates of PFS for recent retrospective studies of second-line (2 L) or second-line and later (2 L+) chemotherapy in patients with mMCC [13–15]. NE, not estimable. a Includes both immunocompetent and immunocompromised patients. All patients progressed; therefore, none were censored. b PFS rate at 6 months was 0%. c One patient with PR had PFS lasting 354 days; 95% of patients receiving second-line chemotherapy had progressed at 230 days
Fig. 2 Survival outcomes in patients with mMCC receiving avelumab. Kaplan-Meier estimates of (a) progression-free survival (PFS) and (b) overall survival (OS). Vertical lines indicate censored events. Also depicted in (a) are Kaplan-Meier estimates of PFS for recent retrospective studies of second-line (2 L) or second-line and later (2 L+) chemotherapy in patients with mMCC [13–15]. NE, not estimable. a Includes both immunocompetent and immunocompromised patients. All patients progressed; therefore, none were censored. b PFS rate at 6 months was 0%. c One patient with PR had PFS lasting 354 days; 95% of patients receiving second-line chemotherapy had progressed at 230 daysCC BY · PubMed Central
Fig. 3 Objective response rates in patient subgroups. The ORR and associated 95% CI values are graphed and shown for the indicated subgroups. MCPyV, Merkel cell polyomavirus; ORR, objective response rate; PD-L1, programmed death-ligand 1; SLD, sum of target lesion diameters. a PD-L1 expression in tumor samples was assessed using a proprietary immunohistochemistry assay (Dako PD-L1 IHC 73-10 pharmDx). Determination of PD-L1–positive status at different PD-L1 cutoff levels was based on tumor cell staining of any intensity
Fig. 3 Objective response rates in patient subgroups. The ORR and associated 95% CI values are graphed and shown for the indicated subgroups. MCPyV, Merkel cell polyomavirus; ORR, objective response rate; PD-L1, programmed death-ligand 1; SLD, sum of target lesion diameters. a PD-L1 expression in tumor samples was assessed using a proprietary immunohistochemistry assay (Dako PD-L1 IHC 73-10 pharmDx). Determination of PD-L1–positive status at different PD-L1 cutoff levels was based on tumor cell staining of any intensityCC BY · PubMed Central
Fig. 4 Response durability in patient subgroups. The proportions of responding patients with response duration ≥1 year are depicted for the indicated patient subgroups. The associated median DOR and 95% CI for each subgroup is shown on the right. DOR, duration of response; MCPyV, Merkel cell polyomavirus; NE, not estimable; NR, not yet reached; PD-L1, programmed death-ligand 1; SLD, sum of target lesion diameters. a One patient missing information on site of the primary tumor had an ongoing response for <1 year (8.8+ months). b Of 3 patients with a response to avelumab and PD-L1–negative status (<1% tumor-cell staining cutoff), the response was ongoing in all 3 patients for <1 year (3.9+, 11.1+, and 11.1+ months)
Fig. 4 Response durability in patient subgroups. The proportions of responding patients with response duration ≥1 year are depicted for the indicated patient subgroups. The associated median DOR and 95% CI for each subgroup is shown on the right. DOR, duration of response; MCPyV, Merkel cell polyomavirus; NE, not estimable; NR, not yet reached; PD-L1, programmed death-ligand 1; SLD, sum of target lesion diameters. a One patient missing information on site of the primary tumor had an ongoing response for <1 year (8.8+ months). b Of 3 patients with a response to avelumab and PD-L1–negative status (<1% tumor-cell staining cutoff), the response was ongoing in all 3 patients for <1 year (3.9+, 11.1+, and 11.1+ months)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 2

  1. Bavencio. (avelumab) injection [package insert]. Darmstadt: Merck KGaA; 2017.
  2. Becker J, Lorenz E, Haas G, Helwig C, Oksen D, Mahnke L, et al. Evaluation of real world treatment outcomes in patients with metastatic Merkel cell carcinoma (MCC) following second line chemotherapy. Ann Oncol 2016;26(Suppl 3 [Abstract 2602]). doi: https://doi.org/10.1158/1538-7445.AM2017-CT074 . · DOI · Paper page

Cited by

See all 334

Metadata

Authors
Kaufman, H. L., Russell, J. S., Hamid, O., Bhatia, S., Terheyden, P., D’Angelo, S. P., Shih, K. C., Lebbé, C., Milella, M., Brownell, I., Lewis, K. D., Lorch, J. H., von Heydebreck, A., Hennessy, M., & Nghiem, P.
Affiliations
  • Rutgers Cancer Institute (US)
  • Moffitt Cancer Center (US)
  • Angeles Clinic and Research Institute (US)
  • University of Washington Medical Center (US)
  • University of Lübeck (DE)
  • Memorial Sloan Kettering Cancer Center (US)
  • Sarah Cannon Research Institute (GB)
  • National Institutes of Health (US)
  • University of Colorado Anschutz (US)
  • Dana-Farber Cancer Institute (US)
  • EMD Serono, Inc. (United States) (US)
Corresponding author
Kaufman, Howard L.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2018-01-19
Volume
6
Issue
1
Pages
7-7
ISSN
2051-1426 (ISSN-L)
OpenAlex
W2783234388
Cited by
334
References
14
Citations by year
2026: 13 · 2025: 15 · 2024: 25 · 2023: 28 · 2022: 21 · 2021: 62 · 2020: 69 · 2019: 71 · 2018: 27
FWCI
21.48
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Merck KGaA, Darmstadt, Germany
  • Pfizer Inc.
Topics
  • Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
  • Health Sciences › Medicine › Dermatology › Nonmelanoma Skin Cancer Studies
  • Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
Keywords
avelumab, Merkel cell carcinoma, metastatic Merkel cell carcinoma, PD-L1 blockade, immune checkpoint inhibitors, long-term follow-up, durable response, progression-free survival, overall survival, Merkel cell polyomavirus, prior chemotherapy, objective response rate, PD-L1 expression, safety and tolerability
MeSH terms
Aged, Antibodies, Monoclonal, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Metastasis, Skin Neoplasms, Time Factors, Carcinoma, Merkel Cell, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. https://app.cochat.ai/papers/10.1186/s40425-017-0310-x
The paper
Kaufman, H. L., Russell, J. S., Hamid, O., Bhatia, S., Terheyden, P., D’Angelo, S. P., Shih, K. C., Lebbé, C., Milella, M., Brownell, I., Lewis, K. D., Lorch, J. H., von Heydebreck, A., Hennessy, M., & Nghiem, P. (2018). Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-017-0310-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.